Efficacy and safety of tofacitinib for moderate and severe ulcerative colitis in real clinical practice: an open observational prospective study
- Authors: Knyazev O.V1,2, Shkurko T.V1,2, Kagramanova A.V1, Lishchinskaya A.A.1, Bordin D.S1,3,4, Parfenov A.I1
-
Affiliations:
- A.S. Loginov Moscow Clinical Scientific and Practical Center
- Research Institute for Healthcare Organization and Medical Management
- Tver State Medical University
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 27, No 2 (2020)
- Pages: 38-44
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312505
- DOI: https://doi.org/10.18565/pharmateca.2020.2.38-44
- ID: 312505
Cite item
Abstract
Full Text
About the authors
O. V Knyazev
A.S. Loginov Moscow Clinical Scientific and Practical Center; Research Institute for Healthcare Organization and Medical ManagementMoscow, Russia
T. V Shkurko
A.S. Loginov Moscow Clinical Scientific and Practical Center; Research Institute for Healthcare Organization and Medical ManagementMoscow, Russia
A. V Kagramanova
A.S. Loginov Moscow Clinical Scientific and Practical CenterMoscow, Russia
Albina A. Lishchinskaya
A.S. Loginov Moscow Clinical Scientific and Practical Center
Email: lalbina@inbox.ru
Cand. Sci. (Med.), Senior Researcher at the Department of Treatment of Inflammatory Bowel Diseases Moscow, Russia
D. S Bordin
A.S. Loginov Moscow Clinical Scientific and Practical Center; Tver State Medical University; A.I. Yevdokimov Moscow State University of Medicine and DentistryMoscow, Russia; Tver, Russia
A. I Parfenov
A.S. Loginov Moscow Clinical Scientific and Practical CenterMoscow, Russia
References
- Хатьков И.Е., Парфенов А.И, Князев О.В. и др. Воспалительные заболевания кишечника в практике терапевта и хирурга. Вита-ПРЕСС, 2017. 120 с.
- Ng S.C., Shi H.Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2018;390:2769-78.
- Cohen R.D., Yu A.P, Wu E.Q., et al. Systematic review: The costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31: 693-707.
- Baghaei A., Emami M.H., Adibi P, et al. Inflammatory Bowel Disease Registry and Monitoring: Feasibility Study and Application (Isfahan Inflammatory Bowel Disease Surveillance Project). Int J Prev Med. 2019;10:190. doi: 10.4103/ijpvm.
- Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohn's Colitis. 2012;6(10):991-1030. Doi: http://dx.doi. org/10.1016/j.crohns.2012.09.002.
- Ивашкин В.Т, Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1(59):6-30.
- Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. М.: Миклош, 2008. 400 c.
- Князев О.В., Чурикова А.А. Антицитокиновая терапия и качество жизни больных воспалительными заболеваниями кишечника. Доказательная гастроэнтерология. 2014;2:17-23.
- Gisbert J.P., Marfn A.C., McNicholl A.G., Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613-23. doi: 10.1111/apt.13083.
- Gordon J.P., McEwan PC., Maguire A., et al. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27(7):804-12. doi: 10.1097/MEG.0000000000000378.
- Белоусова E.A., Халиф И.Л., Абдулганиева Д.И. и др. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(6):445-63. doi: 10.18786/2072-0505-2018-46-6445-463.
- Yanal H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-98.
- Peyrin-Biroulet L., Van Assche G., Sturm A., et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis. 2016;48(6):601-7. doi: 10.1016/j.dld.2016.01.013.
- Banerjee S., Biehl A., Gadina M., et al. JAKSTAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77(5):521-46. doi: 10.1007/s40265017-0701-9.
- Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14(5):269-78. Doi: 10.1038/ nrgastro.2016.208.
- Шапина M.B., Халиф И.Л. Эффективность и безопасность тофацитиниба при язвенном колите (обзор литературы). Колопроктология. 2018;3:94-102.
- Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-29.
- Hanauer S., Panaccione R., Danese S., et al. Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2. J Crohn's Colitis. 2018;12:S046-S048. Doi: https://doi. org/10.1093/ecco-jcc/jjxl80.061.
- Feagan B.G., Dubinsky M.C., Lukas et al. Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction nonresponders. J Crohn's Colitis. 2018;12:S050. Doi: https://doi. org/W.W93/ecco-jcc/jjxl80.064.
- Weisshof R., Aharoni Golan M., Sossenheimer P.H., et al. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019;64(7):1945-51. doi: 10.1007/sl0620-019-05492-y.
- Ungaro R., Fenster M., Dimopoulos C., et al. Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. J Crohn's Colitis. 2019;13:S274-S275. Doi: https://doi. org/10.1093/ecco-jcc/jjy222.468.
- Lair-Mehiri L., Stefanescu S., Vaysse T., et al. Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. J Crohn's Colitis. 2019;13:S478-S479. Doi: https://doi. org/10.1093/ecco-jcc/jjy222.839.
- Rubin D.T., Ashaye A.O., Zhang Y., et al. Comparative efficacy and safety of tofacitinib and biologies as induction therapy for moderately-to-severely active ulcerative colitis: a systematic review and network meta-analysis. Presented at: 25th United European Gastroenterology Week 2017. Barcelona, Spain, 28 October, 2017(1).
- Bonovas S., Lytras T., Nikolopoulos G., et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454-65. doi: 10.1111/apt.14449.
- Singh S., Fumery M., Sandborn W., et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162-75. doi: 10.1111/apt.l4422.
- Белоусова E.A., Абдулганиева Д.И., Алексеева О.П., и др. Опыт применения тофацитиниба в терапии язвенного колита в условиях реальной клинической практики. Колопроктология. 2019;18(4):86-99. Doi: https:// doi.org/10.33878/2073-7556-2019-18-4-86-99.